Search alternatives:
point decrease » point increase (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 1,321 - 1,340 results of 227,959 for search '(( 5 ((nn decrease) OR (mean decrease)) ) OR ( a ((point decrease) OR (a decrease)) ))', query time: 1.11s Refine Results
  1. 1321
    Graph for maximum Frequency at G<sub>y</sub> = 0.

    Graph for maximum Frequency at G<sub>y</sub> = 0. by Muhammad Hammad Bucha (21736111)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 1322
    Graph for maximum Power at G<sub>y</sub> = 0.

    Graph for maximum Power at G<sub>y</sub> = 0. by Muhammad Hammad Bucha (21736111)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 1323
    Summary of experimentation results.

    Summary of experimentation results. by Muhammad Hammad Bucha (21736111)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 1324
    Piezoelectric eel.

    Piezoelectric eel. by Muhammad Hammad Bucha (21736111)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 1325
    Panel probit models: Dummy variable which takes a value of 1 for a top 5 publication.

    Panel probit models: Dummy variable which takes a value of 1 for a top 5 publication. by Sergey V. Popov (6719075)

    Published 2022
    Save to List
    Saved in:
  6. 1326
    Correlates of osteogenic differentiation.

    Correlates of osteogenic differentiation. by Fabian Westhauser (5314436)

    Published 2019
    Save to List
    Saved in:
  7. 1327
    Table 1_Subjective spatial orientation discomfort is associated with decreased real-world spatial performance and lower cognitive function.docx

    Table 1_Subjective spatial orientation discomfort is associated with decreased real-world spatial performance and lower cognitive function.docx by Johannes Gerb (10287758)

    Published 2024
    Save to List
    Saved in:
  8. 1328
    D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis.

    D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

    Published 2020
    Save to List
    Saved in:
  9. 1329
    D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis.

    D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

    Published 2020
    Save to List
    Saved in:
  10. 1330
    Conditional PyLT expression induces cell cycle progression, an increase in cyclin A and a decrease in p21 in ICI treated cells.

    Conditional PyLT expression induces cell cycle progression, an increase in cyclin A and a decrease in p21 in ICI treated cells. by Hemant Varma (30590)

    Published 2007
    Save to List
    Saved in:
  11. 1331
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 1332
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 1333
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 1334
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1335
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 1336
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 1337
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 1338
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 1339
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 1340
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: